Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Aberrant immunoexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts

dc.contributor.authorEscobar, Enrico
dc.contributor.authorGómez Valenzuela, Fernán
dc.contributor.authorPeñafiel, Cristian
dc.contributor.authorChimenos Küstner, Eduardo
dc.contributor.authorPérez-Tomás, Ricardo
dc.date.accessioned2025-03-18T16:03:38Z
dc.date.available2025-03-18T16:03:38Z
dc.date.issued2023-01-15
dc.date.updated2025-03-18T16:03:38Z
dc.description.abstractBackground: The growth of ameloblastomas (odontogenic tumours) and odontogenic keratocyst (OKC) (developmental cyst) is associated with the expression of proteins related to cell survival and apoptosis. Bcl-2-associated protein X (Bax) and the tumour suppressor protein p53 collectively promote p53-mediated apoptosis. This study aimed to assess the immunohistochemical expression of p53, Bcl-2 and Bax in conventional ameloblastoma (CA), unicystic ameloblastoma (UA) types, and OKC sporadic (OKC-NS/S) and syndromic (OKC-NBSCC). Material and Methods: Paraffinized blocks of CA (n=18), UA (n=15), OKC-NS/S (n=18) and OKC-NBSCC (n=15) fixed in 10% formalin were used. After diagnosis, tissue specimens were stained by immunohistochemistry for p53, Bcl-2 and Bax marker. Stained cells were randomly counted in five high power fields. The data analysis was performed via Shapiro-Wilk test, ANOVA with Tukey’s multiple comparisons or Kruskal-Wallis with Dunn’s multiple comparisons. Statistical significance was defined as p<0.05. Results: We did not observe differences between p53 expression in CA, mural UA (MUA), intraluminal/luminal UA (I/LUA), OKC-NS/S, and OKC-NBSCC (19.69%, 18.74%, 16.76%, 12.35% and 9.04%, respectively). Similar results were recognized for Bax expression in CA, MUA, I/LUA, OKC-NS/S, and OKC-NBSCC (33.72%, 34.95%, 22.94, 21.58% and 20.76%, respectively). However, we recognized significant differences between Bcl-2 expression in OKC-NS/S vs MUA, OKC-NS/S vs I/LUA, OKC-NS/S vs CA, OKC-NBSCC vs MUA, OKCNBSCC vs I/LUA, and I/LUA vs CA. P53, Bcl-2 and Bax levels were higher in mural morphological areas versus intraluminal and luminal morphological areas in UA. Conclusions: There is a tendency for an increased expression of p53, Bcl-2, and Bax proteins in CA, and mural proliferation of UA, compared to lesions with a cystic morphology, which could be associated with a local aggressive behaviour.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec730517
dc.identifier.issn1989-5488
dc.identifier.pmid36911151
dc.identifier.urihttps://hdl.handle.net/2445/219808
dc.language.isoeng
dc.publisherMedicina Oral SL
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.4317/jced.59769
dc.relation.ispartofJournal of Clinical and Experimental Dentistry, 2023, vol. 15, num.2, p. e125-e134
dc.relation.urihttps://doi.org/10.4317/jced.59769
dc.rights(c) Medicina Oral SL, 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCàncer de boca
dc.subject.classificationProteïnes supressores de tumors
dc.subject.classificationApoptosi
dc.subject.otherOral cancer
dc.subject.otherTumor suppressor protein
dc.subject.otherApoptosis
dc.titleAberrant immunoexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
257518.pdf
Mida:
5.69 MB
Format:
Adobe Portable Document Format